This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Lonza Inc.. Active years: 2020-2022.
Company Filing History:
Years Active: 2020-2022
Title: Innovations of Christopher Mark Smales
Introduction
Christopher Mark Smales is a notable inventor based in Canterbury, GB. He has made significant contributions to the field of biotechnology, particularly in the modulation of lipid metabolism and protein production. With a total of 3 patents, his work has implications for the development of next-generation biologics.
Latest Patents
One of his latest patents is titled "Modulation of lipid metabolism for protein production." This patent features methods and compositions aimed at improving the production and quality of recombinant products. The methods include introducing a lipid metabolism modulator to a cell or a cell-free system. Additionally, the patent encompasses engineered cells with enhanced production capacity and improved product quality.
Another significant patent is "Inhibition of protein degradation for improved production." This patent discloses methods and compositions for evaluating and selecting cells with improved production capacity. The methods involve modulating the protein degradation pathway using various inhibitors, which can lead to higher yields and better quality products.
Career Highlights
Christopher Mark Smales is currently associated with Lonza Inc., a leading company in the life sciences sector. His work at Lonza focuses on advancing biotechnological methods that enhance product quality and production efficiency. His innovative approaches have positioned him as a key figure in his field.
Collaborations
Throughout his career, Christopher has collaborated with talented individuals such as Tanya Jeane Knight and James Budge. These collaborations have further enriched his research and development efforts, leading to impactful innovations.
Conclusion
Christopher Mark Smales exemplifies the spirit of innovation in biotechnology. His patents and work at Lonza Inc. contribute significantly to advancements in protein production and quality. His ongoing efforts continue to shape the future of biologics and biotechnology.